Safer In Vitro Drug Screening Models for Melioidosis Therapy Development
Anna S Amiss1, Jessica R Webb2, Mark Mayo2
1Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
Abstract:
Melioidosis is a neglected tropical disease caused by the Gram-negative soil bacterium Burkholderia pseudomallei. Current antibiotic regimens used to treat melioidosis are prolonged and expensive, and often ineffective because of intrinsic and acquired antimicrobial resistance. Efforts to develop new treatments for melioidosis are limited by the risks associated with handling pathogenic B. pseudomallei, which restricts research to facilities with biosafety level three containment. Closely related nonpathogenic Burkholderia can be investigated under less stringent biosafety level two containment, and we hypothesized that they could be used as model organisms for developing therapies that would also be effective against B. pseudomallei. We used microbroth dilution assays to compare drug susceptibility profiles of three B. pseudomallei strains and five nonpathogenic Burkholderia strains. Burkholderia humptydooensis, Burkholderia thailandensis, and Burkholderia territorii had similar susceptibility profiles to pathogenic B. pseudomallei that support their potential as safer in vitro models for developing new melioidosis therapies.
Insights
Nonpathogenic Burkholderia species can serve as safer models for developing new melioidosis treatments. These bacteria exhibit similar drug susceptibility profiles to the pathogenic Burkholderia pseudomallei, enabling research under lower biosafety levels.
Area of Science:
- Microbiology
- Infectious Diseases
- Drug Discovery
Background:
- Melioidosis, a neglected tropical disease, is caused by Burkholderia pseudomallei.
- Current melioidosis treatments are lengthy, costly, and often fail due to antimicrobial resistance.
- Research on B. pseudomallei is restricted to high-containment facilities (biosafety level 3).
Purpose of the Study:
- To evaluate the potential of nonpathogenic Burkholderia species as in vitro models for melioidosis therapy development.
- To compare the antimicrobial susceptibility profiles of nonpathogenic and pathogenic Burkholderia strains.
- To identify safer alternatives for studying melioidosis treatment strategies.
Main Methods:
- Microbroth dilution assays were employed.
- Drug susceptibility profiles of three B. pseudomallei strains were compared with five nonpathogenic Burkholderia strains.
- Comparative analysis of antimicrobial resistance patterns was conducted.
Main Results:
- Three nonpathogenic species—Burkholderia humptydooensis, Burkholderia thailandensis, and Burkholderia territorii—showed similar drug susceptibility profiles to pathogenic B. pseudomallei.
- These findings support the utility of these nonpathogenic species as surrogates.
- The study identified specific nonpathogenic strains suitable for lower biosafety level research.
Conclusions:
- Nonpathogenic Burkholderia species, such as B. humptydooensis, B. thailandensis, and B. territorii, can serve as effective and safer in vitro models for melioidosis research.
- Utilizing these models facilitates the development of novel melioidosis therapies under less stringent biosafety conditions (biosafety level 2).
- This approach addresses the limitations imposed by the pathogenicity of B. pseudomallei, accelerating therapeutic innovation.
